Additionally, no significant difference was found in the occurrence rate of other ICI-associated endocrinopathies between patients on anti-PD-L1 therapy and those on anti-PD-1 therapy (χ2 = 0.043, p = 0.836). This evidence concerns the gene CD274 and endocrine system disorder.